Key Takeaways
- Childhood Cancer International-Europe emphasizes equal access to new medicines for children worldwide.
- CCI-Europe will engage patients and caregivers in Health Technology Assessments starting January 2025.
- The organization encourages participation in discussions on best practices for patient involvement in health assessments.
Childhood Cancer International-Europe (CCI-Europe) recently shared a post on LinkedIn, advocating for equal access to new medications for children with cancer, regardless of their location. The organization participated in a significant meeting of the HTA Stakeholder Group, a forum organized by the European Commission aimed at enhancing the implementation of the new Health Technology Assessment (HTA) regulation.
Beginning January 2025, CCI-Europe will play a key role in identifying individual patients, including parents and survivors of specific childhood cancers. These individuals will provide essential insights and perspectives regarding their experiences, which will be vital for the HTA process. The primary goal is to ensure that the voices of those directly affected by childhood cancer are included in discussions about new treatments and health assessments.
CCI-Europe is encouraging community members to engage with these discussions, exchange best practices, and help establish key indicators for effective patient involvement in the health technology assessment process. The organization seeks to foster an inclusive environment where experiences and concerns can be shared, ultimately improving access to new therapies for children with cancer.
Participation in these focus groups will be crucial as they shape the future of how health assessments will operate within the European healthcare landscape. CCI-Europe invites individuals interested in becoming part of this initiative to learn more and join the conversations that will impact the lives of many children facing cancer. Through this collaborative effort, CCI-Europe aims to make significant contributions to the accessibility of innovative treatments for pediatric cancer patients.
The content above is a summary. For more details, see the source article.
